A selective p53 activator and anticancer agent to improve colorectal cancer therapy

Autor: Helena Ramos, Maria I.L. Soares, Joana Silva, Liliana Raimundo, Juliana Calheiros, Célia Gomes, Flávio Reis, Filipe A. Monteiro, Cláudia Nunes, Salette Reis, Bartolomeo Bosco, Silvano Piazza, Lucília Domingues, Petr Chlapek, Petr Vlcek, Pavel Fabian, Ana Teresa Rajado, A.T.P. Carvalho, Renata Veselska, Alberto Inga, Teresa M.V.D. Pinho e Melo, Lucília Saraiva

Publikováno v: Cell Reports, Vol 35, Iss 2, Pp 108982- (2021)

Summary: Impairment of the p53 pathway is a critical event in cancer. Therefore, reestablishing p53 activity has become one of the most appealing anticancer therapeutic strategies. Here, we disclose the p53-activating anticancer drug (3S)-6,7-bis(hyd

Externí odkaz: https://doaj.org/article/49516e7fa22e429b9dc9fbabff3cfc73

Exploiting DNA Damage Repair in Precision Cancer Therapy: BRCA1 as a Prime Therapeutic Target

Autor: Juliana Calheiros, Lucília Saraiva, Liliana Raimundo

Publikováno v: Cancers, Vol 13, Iss 3438, p 3438 (2021)
Cancers

Simple Summary Chemical inhibition of central DNA damage repair (DDR) proteins has become a promising approach in precision cancer therapy. In particular, BRCA1 and its DDR-associated proteins constitute important targets for developing DNA repair in

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::700bbde97a6973edd41446fac4769884
https://www.mdpi.com/2072-6694/13/14/3438

Targeting p53 for Melanoma Treatment: Counteracting Tumour Proliferation, Dissemination and Therapeutic Resistance

Autor: Joana B. Loureiro, Liliana Raimundo, Marco G. Alves, Célia Gomes, Maria Inês Almeida, Carla Carvalho, Lucília Saraiva, José Luis Costa, Nuno R. Lima, Valentina Barcherini, Juliana Calheiros, Maria M. M. Santos

Publikováno v: Cancers, Vol 13, Iss 1648, p 1648 (2021)
Cancers
Volume 13
Issue 7
Repositório Científico de Acesso Aberto de Portugal
Repositório Científico de Acesso Aberto de Portugal (RCAAP)
instacron:RCAAP

Melanoma is the deadliest form of skin cancer, primarily due to its high metastatic propensity and therapeutic resistance in advanced stages. The frequent inactivation of the p53 tumour suppressor protein in melanomagenesis may predict promising outc

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::bf7d824d785e389090f4712177c20c8c
https://www.mdpi.com/2072-6694/13/7/1648

Targeting p53 with SLMP53-2 for melanoma treatment: counteracting tumour proliferation, dissemination and therapeutic resistance

Autor: Célia Gomes, Liliana Raimundo, Valentina Barcherini, Joana A. Loureiro, Nuno R. Lima, Maria Mm Santos, José Carlos Costa, Lucília Saraiva, Marco G. Alves, Juliana Calheiros, Inês Almeida

Background and purpose: Melanoma is the deadliest form of skin cancer mostly due to its high metastatic propensity and therapeutic resistance in advanced stages. The frequent inactivation of the p53 tumour suppressor protein in melanomagenesis may pr

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_________::86485db8784f8fba86bbd7c6ba5fa049
https://doi.org/10.22541/au.160456338.88634220/v1

SLMP53-1 Inhibits Tumor Cell Growth through Regulation of Glucose Metabolism and Angiogenesis in a P53-Dependent Manner

Autor: Helena Ramos, Valentina Barcherini, Joana Almeida, Lucília Saraiva, Alexandra T. P. Carvalho, Juliana Calheiros, Sónia F. G. Santos, Maria M. M. Santos

Publikováno v: International Journal of Molecular Sciences
International Journal of Molecular Sciences, Vol 21, Iss 2, p 596 (2020)

The Warburg effect is an emerging hallmark of cancer, which has the tumor suppressor p53 as its major regulator. Herein, we unveiled that p53 activation by (S)-tryptophanol-derived oxazoloisoindolinone (SLMP53-1) mediated the reprograming of glucose

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::ec9b02837293cf7bcebe64d4dcc8ddd3
http://europepmc.org/articles/PMC7013701